Avalo Therapeutics promotes Garry Neil to CEO and Chris Sullivan to CFO, replaces Cola and Greenway

Avalo Therapeutics, Inc.

Garry Neil appointed CEO from CSO; base salary $475K/yr, option for 1M shares vesting 4 years.
Chris Sullivan appointed CFO from CAO; base salary $350K/yr, $50K bonus, option for 400K shares.
Former CEO Michael Cola and CFO Schond Greenway terminated effective Feb 14, 2022.
Neil serves as Chairman of Arena Pharmaceuticals (ARNA), a ~$6B Nasdaq biotech.
Sullivan previously helped raise ~$80M in gross proceeds as interim CFO.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Role change

Christopher Sullivan

Chief Financial Officer

AVTX · Avalo Therapeutics, Inc.

Effective: 2022-02-14
Filed: February 18, 2022, 6:59 PM ET

On February 14, 2022, the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Garry A. Neil as President and Chief Executive Officer of the Company and Christopher Sullivan as Chief Financial Officer, effective February 14, 2022.

Role change

Garry A. Neil

President and Chief Executive Officer

AVTX · Avalo Therapeutics, Inc.

Effective: 2022-02-14
Filed: February 18, 2022, 6:59 PM ET

On February 14, 2022, the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Garry A. Neil as President and Chief Executive Officer of the Company and Christopher Sullivan as Chief Financial Officer, effective February 14, 2022.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Christopher Sullivan was appointed as Chief Financial Officer at Avalo Therapeutics, Inc..

Action: appointed
Role: Chief Financial Officer

Exact text from the filing

On February 14, 2022, the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Garry A. Neil as President and Chief Executive Officer of the Company and Christopher Sullivan as Chief Financial Officer, effective February 14, 2022.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Garry A. Neil was appointed as President and Chief Executive Officer at Avalo Therapeutics, Inc..

Action: appointed
Role: President and Chief Executive Officer

Exact text from the filing

On February 14, 2022, the Board of Directors (the “Board”) of Avalo Therapeutics, Inc. (the “Company”) appointed Garry A. Neil as President and Chief Executive Officer of the Company and Christopher Sullivan as Chief Financial Officer, effective February 14, 2022.

View on SEC.gov

Avalo Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001628280-22-003178

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.